Evidence map›Paper›PMID 34359641›Full record

ArticleCancers2021

Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634.

Florence Atrafi, Ruben A G van Eerden, Stijn L W Koolen, Peter de Bruijn, Cristianne J F Rijcken, Rob Hanssen, Ferry A L M Eskens, Martijn P Lolkema, Esther Oomen-de Hoop, Jeffrey Damman and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Florence AtrafiDepartment of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0003-3659-0391
Ruben A G van EerdenDepartment of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Stijn L W KoolenDepartment of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Peter de BruijnDepartment of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0003-3372-5756
Cristianne J F RijckenCristal Therapeutics, 6229 EV Maastricht, The Netherlands.
Rob HanssenCristal Therapeutics, 6229 EV Maastricht, The Netherlands.
Ferry A L M EskensDepartment of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Martijn P LolkemaDepartment of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Esther Oomen-de HoopDepartment of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0003-2506-3852
Jeffrey DammanDepartment of Pathology, Erasmus MC, 3015 GD Rotterdam, The Netherlands.
Ron H J MathijssenDepartment of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0001-5667-5697
Erasmus MC Cancer Institute · NLCristal Therapeutics (Netherlands) · NLErasmus MC · NL

Funding

Cristal Therapeutics NA
6 · The paper itself

Abstract

Docetaxel entrapped nanoparticle CPC634 is associated with dose-related skin toxicity that resembles conventional docetaxel (Cd)-related skin toxicity. This study compared the cutaneous pharmacokinetics and pharmacodynamics of docetaxel and CPC634. In this randomised cross-over study, patients with solid tumours received one cycle of CPC634 and Cd (both at 75 mg/m

Indexed as

chemotherapydocetaxelnanoparticlespharmacodynamicspharmacokineticsskintoxicity

Identifiers

PMID34359641
PMCPMC8345028
OpenAlexW3183138907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.